Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer

被引：0
|
作者：
Spring, L. M. [1 ,2 ]
Han, H. [3 ]
Hamilton, E. [4 ]
Irie, H. [5 ]
Santa-Maria, C. A. [6 ]
Reeves, J. [7 ]
Pan, P. [8 ]
Shan, M. [8 ]
Tang, Y. [8 ]
Graham, J. R. [8 ]
Hazard, S. [8 ]
Ellisen, L. W. [1 ,2 ]
Isakoff, S. J. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Tampa, FL USA
[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Sarah Cannon Res Inst, Florida Canc Specialists South, Ft Myers, FL USA
[8] GSK, Waltham, MA USA
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P095
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [41] PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Conte, Benedetta
    Martel, Samuel
    Maurer, Christian
    Tagliamento, Marco
    Viglietti, Giulia
    Del Mastro, Lucia
    De Azambuja, Evandro
    Lambertini, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Adjuvant Olaparib in BRCA-Mutated Breast Cancer REPLY
    Tutt, Andrew N. J.
    Garber, Judy E.
    Geyer, Charles E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1440 - 1440
  • [43] Cost-effectiveness for companion BRCA testing and adjuvant olaparib treatment in patients with BRCA mutated high-risk HER2-negative early breast cancer
    Sheppard, E.
    Ma, W.
    Punekar, Y.
    Sagoo, G.
    Nikolova, S.
    VIRCHOWS ARCHIV, 2024, 485 : S347 - S347
  • [44] An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Bang, Yung-Jue
    Park, Yeonh H.
    Alexandre, Jerome
    Delord, Jean-Pierre
    Italiano, Antoine
    You, Benoit
    Bastian, Sara
    Krebs, Matthew
    Wang, Ding
    Waqar, Saiama
    Angell, Helen
    Learoyd, Maria
    Chang, Shao-Chun
    Gresty, Christopher
    Herbolsheimer, Pia
    Kaufman, Bella
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
    Angell, Helen
    Ros, Vidalba Rocher
    Standifer, Nathan
    Lai, Zhongwu
    Gresty, Christopher
    Delord, Jean-Pierre
    De Jonge, Maja
    Postel-Vinay, Sophie
    Italiano, Antoine
    Krebs, Matthew G.
    Kaufman, Bella
    Park, Yeon Hee
    Domchek, Susan
    Herbolsheimer, Pia
    Hodgson, Darren
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [46] Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
    Caramelo, Olga
    Silva, Cristina
    Caramelo, Francisco
    Frutuoso, Cristina
    Pinto, Leonor
    Almeida-Santos, Teresa
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)
  • [47] Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
    Olga Caramelo
    Cristina Silva
    Francisco Caramelo
    Cristina Frutuoso
    Leonor Pinto
    Teresa Almeida-Santos
    Hereditary Cancer in Clinical Practice, 20
  • [48] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [49] Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
    Lucas, Mairi W.
    Kelly, Catherine M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2493 - 2506
  • [50] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
12345